甲基苯丙胺相关心力衰竭:观察性研究的系统综述
MethHF患病率上升,累及多样人群且男性为主,高达44%保留左室射血分数,发病率显著。女性、戒除甲基苯丙胺和指南导向心衰治疗与更好结局相关。
要点
- MethHF患病率上升,男性为主,高达44%保留左室射血分数。
- 戒除甲基苯丙胺是MethHF治疗不可或缺的部分。
- 女性、戒断和指南导向心衰治疗与更好结局相关。
核心结论
- MethHF患病率上升且伴显著发病率,亟需精心设计的前瞻性研究准确评估其流行病学、临床特征、疾病轨迹和结局。
- 戒除甲基苯丙胺是MethHF治疗不可或缺的部分,增加有效非药物干预是 essential first step。
研究设计与样本
- 系统综述,检索6个数据库的原创出版物,标题/摘要和全文双人审核,数据提取和偏倚风险批判性评估双人进行。
主要发现
- 因研究设计、人群、对照和结局评估异质性,结果无法合并。
- 总体偏倚风险中等,因存在混杂因素、选择偏倚和匹配不佳;总体证据确定性极低。
- MethHF患病率上升,累及多样种族/民族/社会人口群体,男性为主;高达44%保留左室射血分数。
- MethHF与显著发病率相关,包括与非甲基苯丙胺相关心衰相比更差的心衰症状。
- 女性、甲基苯丙胺戒断和指南导向心衰治疗与改善的结局相关;超声心动图心腔尺寸和活检纤维化预测戒断后恢复程度。
临床怎么用
- 戒除甲基苯丙胺是MethHF治疗不可或缺的部分,应增加有效非药物干预治疗甲基苯丙胺成瘾。
- 使用减害原则在整合成瘾/心衰治疗项目中,以遏制MethHF上升趋势。
- 女性、戒断和指南导向心衰治疗与更好结局相关,临床应关注这些因素。
局限性
- 研究设计、人群、对照和结局评估异质性导致结果无法合并。
- 总体偏倚风险中等,因存在混杂因素、选择偏倚和匹配不佳。
- 总体证据确定性极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To conduct a systematic review of observational studies on methamphetamine-associated heart failure (MethHF) . METHODS: Six databases were searched for original publications on the topic. Title/abstract and included full-text publications were reviewed in duplicate. Data extraction and critical appraisal for risk of bias were performed in duplicate. RESULTS: Twenty-one studies are included in the final analysis. Results could not be combined because of heterogeneity in study design, population, comparator, and outcome assessment. Overall risk of bias is moderate due to the presence of confounders, selection bias and poor matching; overall certainty in the evidence is very low. MethHF is increasing in prevalence, affects diverse racial/ethnic/sociodemographic groups with a male predominance; up to 44% have preserved left-ventricular ejection fraction. MethHF is associated with significant morbidity including worse heart failure symptoms compared with non-methamphetamine related heart failure. Female sex, methamphetamine abstinence and guideline-directed heart failure therapy are associated with improved outcomes. Chamber dimensions on echocardiography and fibrosis on biopsy predict the extent of recovery after abstinence. CONCLUSIONS: The increasing prevalence of MethHF with associated morbidity underscores the urgent need for well designed prospective studies of people who use methamphetamine to accurately assess the epidemiology, clinical features, disease trajectory and outcomes of MethHF. Methamphetamine abstinence is an integral part of MethHF treatment; increased availability of effective non-pharmacological interventions for treatment of methamphetamine addiction is an essential first step. Availability of effective pharmacological treatment for methamphetamine addiction will further support MethHF treatment. Using harm reduction principles in an integrated addiction/HF treatment programme will bolster efforts to stem the increasing tide of MethHF.
引用
- Manja, Nrusimha, Gao, et al. Methamphetamine-associated heart failure: a systematic review of observational studies. Heart. 2023. PMID: 36456204. doi:10.1136/heartjnl-2022-321610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。